Aliases & Classifications for Personality Disorder

MalaCards integrated aliases for Personality Disorder:

Name: Personality Disorder 12 29 15
Personality Disorders 55 43 73
Character Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1510
ICD9CM 35 301.8 301.89
ICD10 33 F60 F60.9

Summaries for Personality Disorder

MedlinePlus : 43 Personality disorders are a group of mental illnesses. They involve long-term patterns of thoughts and behaviors that are unhealthy and inflexible. The behaviors cause serious problems with relationships and work. People with personality disorders have trouble dealing with everyday stresses and problems. They often have stormy relationships with other people. The cause of personality disorders is unknown. However, genes and childhood experiences may play a role. The symptoms of each personality disorder are different. They can mild or severe. People with personality disorders may have trouble realizing that they have a problem. To them, their thoughts are normal, and they often blame others for their problems. They may try to get help because of their problems with relationships and work. Treatment usually includes talk therapy and sometimes medicine.

MalaCards based summary : Personality Disorder, also known as personality disorders, is related to schizoid personality disorder and obsessive-compulsive personality disorder, and has symptoms including sleep disturbances, photophobia and personality changes. An important gene associated with Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Fluvoxamine and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are shRNA abundance <= 50% and behavior/neurological

Disease Ontology : 12 A disease of mental health that involve long-term patterns of thoughts and behaviors that cause serious problems with relationships and work.

Wikipedia : 76 Personality disorders (PD) are a class of mental disorders characterized by enduring maladaptive... more...

Related Diseases for Personality Disorder

Diseases in the Personality Disorder family:

Multiple Personality Disorder

Diseases related to Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 182)
# Related Disease Score Top Affiliating Genes
1 schizoid personality disorder 34.4 HTR1A HTR2A
2 obsessive-compulsive personality disorder 33.7 DRD3 SLC6A4
3 dependent personality disorder 33.4 DRD4 MAOA MAOB
4 antisocial personality disorder 31.2 ALDH2 COMT DRD2 HTR1B MAOA MAOB
5 borderline personality disorder 30.8 BDNF COMT HTR1A HTR1B HTR2A HTR2C
6 agoraphobia 30.8 HTR1A MAOA SLC6A4
7 social phobia 30.7 DRD2 HTR1A MAOA SLC6A4
8 alexithymia 30.4 COMT DRD2 HTR1A SLC6A4
9 dysthymic disorder 30.4 HTR2A MAOA SLC6A4
10 kleptomania 30.2 HTR1A MAOA SLC6A4
11 anorexia nervosa 29.9 BDNF COMT HTR2A SLC6A4
12 brain injury 29.8 BDNF COMT DRD2
13 schizophreniform disorder 29.8 COMT DRD2
14 impulse control disorder 29.8 DRD2 DRD3 DRD4
15 heroin dependence 29.7 BDNF DRD2 DRD4
16 cocaine abuse 29.7 DRD2 SLC6A3 SLC6A4
17 traumatic brain injury 29.6 BDNF COMT DRD2
18 chronic fatigue syndrome 29.5 COMT HTR1A MAOA SLC6A4 TPH2
19 postpartum depression 29.5 BDNF COMT HTR1A MAOA SLC6A4
20 bulimia nervosa 29.2 BDNF COMT HTR1B HTR2A MAOA SLC6A4
21 cocaine dependence 29.1 DRD2 DRD3 SLC6A3 SLC6A4
22 eating disorder 28.9 BDNF COMT DRD2 HTR2C SLC6A3 SLC6A4
23 drug dependence 28.9 BDNF DRD2 DRD3 SLC6A4
24 paranoid schizophrenia 28.7 BDNF COMT HTR2A MAOA SLC6A4 TPH2
25 opiate dependence 28.7 DRD2 DRD3 SLC6A4 TPH1
26 conduct disorder 28.6 ALDH2 COMT DRD2 DRD4 MAOA SLC6A3
27 depression 28.6 BDNF HTR1A HTR2A HTR2C MAOA SLC6A4
28 bipolar i disorder 28.5 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
29 delusional disorder 28.4 DRD2 DRD3 DRD4
30 generalized anxiety disorder 28.3 BDNF DRD2 HTR1A HTR2A MAOA SLC6A4
31 anxiety 28.0 BDNF COMT HTR1A HTR2A HTR2C MAOA
32 post-traumatic stress disorder 27.9 BDNF COMT DRD2 HTR2A MAOA MAOB
33 schizoaffective disorder 27.6 BDNF COMT DRD2 DRD3 HTR2A SLC6A4
34 panic disorder 27.6 BDNF COMT HTR1A HTR2A HTR2C MAOA
35 oppositional defiant disorder 27.4 COMT DRD2 DRD4 MAOA SLC6A3 SLC6A4
36 tobacco addiction 27.2 ALDH2 COMT DRD2 HTR2A MAOA SLC6A3
37 substance dependence 26.7 BDNF DRD2 DRD3 DRD4 HTR1B MAOA
38 alcohol abuse 26.7 ALDH2 BDNF DRD2 DRD3 DRD4 SLC6A4
39 substance abuse 26.3 BDNF COMT DRD2 DRD3 DRD4 HTR1B
40 pathological gambling 25.8 DRD2 DRD3 DRD4 HTR2A MAOA MAOB
41 autism 24.1 BDNF COMT DRD2 DRD3 DRD4 HTR1A
42 bipolar disorder 24.0 BDNF COMT DRD2 DRD3 DRD4 HTR1A
43 disease of mental health 23.8 ALDH2 BDNF COMT DRD2 DRD3 DRD4
44 obsessive-compulsive disorder 23.4 BDNF COMT DRD2 DRD3 DRD4 HTR1A
45 major depressive disorder 23.3 BDNF COMT DRD2 DRD3 DRD4 HTR1A
46 psychotic disorder 23.1 BDNF COMT DRD2 DRD3 DRD4 HTR1A
47 mood disorder 22.8 BDNF COMT DRD2 DRD3 DRD4 HTR1A
48 schizophrenia 22.8 BDNF COMT DRD2 DRD3 DRD4 HTR1A
49 attention deficit-hyperactivity disorder 22.4 BDNF COMT DRD2 DRD3 DRD4 HTR1A
50 alcohol dependence 21.4 ALDH2 BDNF COMT DRD2 DRD3 DRD4

Comorbidity relations with Personality Disorder via Phenotypic Disease Network (PDN): (show all 14)


Acute Cystitis Alzheimer Disease
Anxiety Deficiency Anemia
Dependent Personality Disorder Dysthymic Disorder
Generalized Anxiety Disorder Heart Disease
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Schizophreniform Disorder

Graphical network of the top 20 diseases related to Personality Disorder:



Diseases related to Personality Disorder

Symptoms & Phenotypes for Personality Disorder

UMLS symptoms related to Personality Disorder:


sleep disturbances, photophobia, personality changes, restlessness, pseudobulbar behavioral symptoms

GenomeRNAi Phenotypes related to Personality Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.28 ALDH2 COMT DRD2 DRD3 DRD4 HTR1A

MGI Mouse Phenotypes related to Personality Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 HTR2C DRD3 ALDH2 DRD4 BDNF HTR1A
2 homeostasis/metabolism MP:0005376 10.17 HTR2C DRD3 ALDH2 DRD4 BDNF HTR1A
3 cardiovascular system MP:0005385 10.09 DRD2 DRD3 HTR1A HTR1B COMT TPH1
4 growth/size/body region MP:0005378 10.07 DRD2 DRD3 ALDH2 BDNF HTR1B SLC6A4
5 endocrine/exocrine gland MP:0005379 10.01 DRD2 ALDH2 BDNF HTR1B COMT HTR2A
6 adipose tissue MP:0005375 9.95 DRD2 HTR2C DRD3 HTR1B TPH1 TPH2
7 integument MP:0010771 9.86 DRD2 HTR2C ALDH2 BDNF TPH1 TPH2
8 nervous system MP:0003631 9.77 HTR2C DRD3 ALDH2 DRD4 BDNF HTR1A
9 muscle MP:0005369 9.7 DRD2 HTR2C HTR1B HTR2A TPH1 SLC6A3
10 taste/olfaction MP:0005394 8.92 BDNF DRD2 TPH2 SLC6A3

Drugs & Therapeutics for Personality Disorder

Drugs for Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 248)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Not Applicable 54739-18-3 3404 5324346
2
Citalopram Approved Phase 4,Phase 3,Phase 2,Not Applicable 59729-33-8 2771
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
4
Risperidone Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 106266-06-2 5073
5
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 113-45-1 4158
6
Cycloserine Approved Phase 4,Phase 3,Phase 2,Not Applicable 68-41-7 401 6234
7
Clomipramine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 303-49-1 2801
8
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
9
Guanfacine Approved, Investigational Phase 4,Phase 2,Not Applicable 29110-47-2 3519
10
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
11
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 54910-89-3 3386
12
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
13
Olanzapine Approved, Investigational Phase 4,Phase 3,Not Applicable 132539-06-1 4585
14
Paroxetine Approved, Investigational Phase 4,Phase 3,Not Applicable 61869-08-7 43815
15
Sertraline Approved Phase 4,Phase 3,Phase 2,Not Applicable 79617-96-2 68617
16
Norepinephrine Approved Phase 4,Phase 3,Not Applicable 51-41-2 439260
17
Topiramate Approved Phase 4,Phase 3 97240-79-4 5284627
18
Haloperidol Approved Phase 4 52-86-8 3559
19
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
20
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
21
Propranolol Approved, Investigational Phase 4 525-66-6 4946
22
Naratriptan Approved, Investigational Phase 4 143388-64-1, 121679-13-8 4440
23
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
24
Maleic acid Experimental Phase 4,Phase 3 110-16-7 444266
25 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3,Not Applicable
30 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
31 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
33 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
36 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
40 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
41 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
42 Parasympatholytics Phase 4,Phase 3,Phase 2,Not Applicable
43 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Dopamine Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
47 Serotonin Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
48 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
50 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 605)
# Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Unknown status NCT00743834 Phase 4 Luvox CR
3 Treatment Youth With Obsessive-Compulsive Disorder Unknown status NCT00708240 Phase 4 Escitalopram
4 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
5 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
6 Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
7 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder Completed NCT00204347 Phase 4 risperidone
8 Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
9 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
10 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4 Fluvoxamine+Methylphenidate hydrochloride;Fluvoxamine+sugar pill
11 D-Cycloserine as an Adjunct to Internet-CBT for OCD Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
12 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4 Ondansetron
13 Deep Brain Stimulation for Obsessive Compulsive Disorder (OCD PMCF) Completed NCT01135745 Phase 4
14 Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4 atypical antipsychotic drug
15 Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD) Completed NCT00796497 Phase 4 ondansetron
16 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder Completed NCT00723060 Phase 4 escitalopram
17 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
18 Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-compulsive Disorder Patients Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
19 Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment Completed NCT00466609 Phase 4 Clomipramine (fluoxetine plus clomipramine);Quetiapine (fluoxetine plus quetiapine);Placebo (fluoxetine plus placebo)
20 Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00464698 Phase 4 Duloxetine
21 Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder Completed NCT00382291 Phase 4 Regular Titration;Placebo;Slow Titration
22 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Completed NCT00211744 Phase 4 topiramate
23 Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00116532 Phase 4 Escitalopram
24 Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
25 Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA) Completed NCT00000388 Phase 4 Anti-ADHD medication
26 Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
27 Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
28 Developing New Clinical Management Strategies Completed NCT02082392 Phase 4 Escitalopram
29 Treatment Trial for Psychogenic Nonepileptic Seizures Completed NCT00835627 Phase 4 sertraline
30 Treatments for Psychogenic Nonepileptic Seizures (NES) Completed NCT00159965 Phase 4 sertraline;placebo
31 Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline. Recruiting NCT03068429 Phase 4 Sertraline Hydrochloride
32 Probiotic Treatment in Adult Obsessive-Compulsive Disorder Recruiting NCT02334644 Phase 4
33 A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder Recruiting NCT00994786 Phase 4 pregabalin;Placebo
34 Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD) Recruiting NCT00182520 Phase 4 Topiramate;placebo
35 Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients Recruiting NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
36 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
37 Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? Active, not recruiting NCT02656342 Phase 4 D-Cycloserine;Placebo
38 Brief Intervention for OCD Fears Suspended NCT02790710 Phase 4 Propanolol;Placebo
39 Pharmacology of Cognition in Schizotypal Personality Disorder Terminated NCT00353379 Phase 4 Guanfacine;Placebo
40 Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated NCT00282165 Phase 4 naratriptan;placebo
41 Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents Terminated NCT00352768 Phase 4 Fluvoxamine maleate;Placebo
42 Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder Terminated NCT00592852 Phase 4 fluoxetine
43 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Terminated NCT00182533 Phase 4 Sertraline;Placebo
44 Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain Withdrawn NCT00227292 Phase 4 Escitalopram;Placebo
45 BOSCOT : A Randomised Controlled Trial of Cognitive Behavioural Therapy in Borderline Personality Disorder Completed NCT00538135 Phase 3
46 Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD) Completed NCT00880919 Phase 3 quetiapine extended-release;Placebo
47 Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder Completed NCT01912391 Phase 3 Selegiline;Placebo (for Selegiline)
48 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate
49 Olanzapine in Patients With Borderline Personality Disorder Completed NCT00091650 Phase 3 Olanzapine;placebo
50 Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder Completed NCT00088036 Phase 3 Olanzapine

Search NIH Clinical Center for Personality Disorder

Genetic Tests for Personality Disorder

Genetic tests related to Personality Disorder:

# Genetic test Affiliating Genes
1 Personality Disorder 29

Anatomical Context for Personality Disorder

MalaCards organs/tissues related to Personality Disorder:

41
Brain, Testes, Cortex, Prefrontal Cortex, Liver, Amygdala, Eye

Publications for Personality Disorder

Articles related to Personality Disorder:

(show top 50) (show all 2250)
# Title Authors Year
1
Exclusion-Proneness in Borderline Personality Disorder Inpatients Impairs Alliance in Mentalization-Based Group Therapy. ( 29910754 )
2018
2
Frontal and temporal cortical volume, white matter tract integrity, and hemispheric asymmetry in schizotypal personality disorder. ( 29454512 )
2018
3
Change in Biased Thinking in a Treatment Based on the Motive-Oriented Therapeutic Relationship for Borderline Personality Disorder. ( 29388899 )
2018
4
Positive psychotic symptoms in patients with borderline personality disorder: a valuable but still not completely understood clinical marker of the illness. ( 29873564 )
2018
5
The effect of methylphenidate on decision making in patients with borderline personality disorder and attention-deficit/hyperactivity disorder. ( 29847836 )
2018
6
Individuals with Borderline Personality Disorder manifest cognitive biases implicated in psychosis. ( 29960939 )
2018
7
Sensitization of the Neural Salience Network to Repeated Emotional Stimuli Following Initial Habituation in Patients With Borderline Personality Disorder. ( 29961363 )
2018
8
Relationships Among Avoidant Personality Disorder, Social Anxiety Disorder, and Normative Personality Traits: A Twin Study. ( 29505386 )
2018
9
Training in Good Psychiatric Management for Borderline Personality Disorder in Residency: An Aide to Learning Supportive Psychotherapy for Challenging-to-Treat Patients. ( 29809114 )
2018
10
Personality Constructs and Paradigms in the Alternative DSM-5 Model of Personality Disorder. ( 29902081 )
2018
11
Episodic memory and consciousness in antisocial personality disorder and conduct disorder. ( 29353574 )
2018
12
Maternal personality disorder symptoms in primary health care: associations with mother-toddler interactions at one-year follow-up. ( 29914432 )
2018
13
On the potential for iatrogenic effects of psychiatric crisis services: The example of dialectical behavior therapy for adult women with borderline personality disorder. ( 29369662 )
2018
14
Erratum - Borderline Personality Disorder Symptom Severity and Sexually Transmitted Infection and HIV Risk in African American Incarcerated Men. ( 29889162 )
2018
15
Borderline personality disorder is equally trait-like and state-like over ten years in adult psychiatric patients. ( 29952598 )
2018
16
Behavioural mimicry and loneliness in borderline personality disorder. ( 29407356 )
2018
17
The Endocannabinoid System, Aggression, and the Violence of Synthetic Cannabinoid Use, Borderline Personality Disorder, Antisocial Personality Disorder, and Other Psychiatric Disorders. ( 29636670 )
2018
18
Variability in phase and amplitude of diurnal rhythms is related to variation of mood in bipolar and borderline personality disorder. ( 29374207 )
2018
19
Abnormal Sensitization of Neural and Behavioral Responses to Socially Relevant Images in Individuals With Borderline Personality Disorder: Implications for Guiding More Effective Targeting of Treatments. ( 29961366 )
2018
20
What influences social outcomes among offenders with personality disorder: A systematic review. ( 29920809 )
2018
21
Psychosocial stress differentially affects emotional empathy in women with borderline personality disorder and healthy controls. ( 29417987 )
2018
22
Differential relations of executive functioning to borderline personality disorder presentations in adolescents. ( 29388349 )
2018
23
Shining lights in dark corners of people's lives: Reaching consensus for people with complex mental health difficulties who are given a diagnosis of personality disorder. ( 29417661 )
2018
24
Transient hallucinations during interpersonal stress in an adolescent with borderline personality disorder. ( 29374970 )
2018
25
Perimenstrual exacerbation of symptoms in borderline personality disorder: evidence from multilevel models and the Carolina Premenstrual Assessment Scoring System. ( 29860953 )
2018
26
Dissecting the elements of borderline personality disorder. ( 29878704 )
2018
27
Continuity between DSM-5 Section II and Section III personality traits for obsessive-compulsive personality disorder. ( 29024130 )
2018
28
Fear of Being Laughed at in Borderline Personality Disorder. ( 29410640 )
2018
29
Enhanced mental imagery and intact perceptual organization in schizotypal personality disorder. ( 29131991 )
2018
30
Quasi-psychosis in covert Narcissistic Personality Disorder-A case report. ( 29272784 )
2018
31
Does Religiosity Reduce Narcissistic Personality Disorder? Examining the Case of Muslim University Students. ( 29691791 )
2018
32
Alliance Rupture and Resolution in Dialectical Behavior Therapy for Borderline Personality Disorder. ( 29388901 )
2018
33
Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. ( 29448136 )
2018
34
Borderline personality disorder and sexual abuse: A systematic review. ( 29407572 )
2018
35
Psychiatrists' motives for practising in-patient compulsory care of patients with borderline personality disorder (BPD). ( 29853014 )
2018
36
Stability of the Pregnancy Obsessive-Compulsive Personality Disorder Symptoms Checklist. ( 29067550 )
2018
37
Features of borderline personality disorder as a mediator of the relation between childhood traumatic experiences and psychosis-like experiences in patients with mood disorder. ( 29353179 )
2018
38
Clinical Components of Borderline Personality Disorder and Personality Functioning. ( 29393279 )
2018
39
Movies in Mind: 'We need to talk about Kevin'-Is an antisocial personality disorder 'born' or 'made'? ( 29676160 )
2018
40
Bruno Klopfer Award Address: Five-Factor Model Personality Disorder Scales. ( 29897255 )
2018
41
Examining the alternative model for personality disorder in daily life: Evidence for incremental validity. ( 29927292 )
2018
42
Examining the DSM-5 alternative model of personality disorders operationalization of obsessive-compulsive personality disorder in a mental health sample. ( 29927297 )
2018
43
Treatment of a Patient with Borderline Personality Disorder Based on Phase-Oriented Model of Eye Movement Desensitization and Reprocessing (EMDR): A Case Report. ( 29892320 )
2018
44
The Role of Negative Affect and Self-Concept Clarity in Predicting Self-Injurious Urges in Borderline Personality Disorder Using Ecological Momentary Assessment. ( 29388895 )
2018
45
Construct Validity of the McLean Screening Instrument for Borderline Personality Disorder in Two Singaporean Samples. ( 29949444 )
2018
46
Reduced white matter integrity in borderline personality disorder: A diffusion tensor imaging study. ( 28922736 )
2018
47
Partners of Individuals with Borderline Personality Disorder: A Systematic Review of the Literature Examining Their Experiences and the Supports Available to Them. ( 29975337 )
2018
48
Emotional responses to receiving peer feedback on opinions in borderline personality disorder. ( 29927294 )
2018
49
The rewarding nature of provocation-focused rumination in women with borderline personality disorder: a preliminary fMRI investigation. ( 29372058 )
2018
50
The effects of working memory load and attention refocusing on delay discounting rates in alcohol use disorder with comorbid antisocial personality disorder. ( 29277285 )
2018

Variations for Personality Disorder

Expression for Personality Disorder

Search GEO for disease gene expression data for Personality Disorder.

Pathways for Personality Disorder

Pathways related to Personality Disorder according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.43 DRD2 DRD3 DRD4 HTR1A HTR1B HTR2A
2
Show member pathways
12.94 COMT DRD2 DRD3 DRD4 MAOA MAOB
3
Show member pathways
12.86 ALDH2 COMT MAOA SLC6A3 SLC6A4
4 12.44 COMT HTR1A TPH1 TPH2
6
Show member pathways
12.17 BDNF DRD2 HTR1A HTR1B
7
Show member pathways
12.12 ALDH2 MAOA MAOB TPH1 TPH2
8 12.08 BDNF HTR1A HTR2A MAOA SLC6A4 TPH1
9
Show member pathways
11.9 BDNF DRD2 MAOA MAOB SLC6A3
10 11.78 DRD3 DRD4 HTR2A
11
Show member pathways
11.78 DRD2 DRD3 DRD4
12
Show member pathways
11.76 DRD2 DRD3 DRD4 HTR1A HTR1B HTR2A
13 11.7 DRD2 HTR2A HTR2C
14 11.66 HTR1A HTR1B HTR2A HTR2C MAOA MAOB
15
Show member pathways
11.63 COMT MAOA MAOB
16
Show member pathways
11.49 ALDH2 MAOA MAOB
17
Show member pathways
11.39 MAOA SLC6A3 SLC6A4 TPH2
18
Show member pathways
11.26 ALDH2 MAOA MAOB
19
Show member pathways
11.07 ALDH2 COMT MAOA SLC6A3 SLC6A4
20
Show member pathways
11.05 COMT MAOA TPH1
21 10.97 DRD2 DRD3
22 10.92 HTR2A HTR2C
23
Show member pathways
10.85 ALDH2 COMT MAOA MAOB
24 10.83 COMT MAOA MAOB
25
Show member pathways
10.78 ALDH2 MAOA MAOB
26 10.67 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4

GO Terms for Personality Disorder

Cellular components related to Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 9.62 SLC6A3 SLC6A4 TPH1 TPH2
2 integral component of plasma membrane GO:0005887 9.61 DRD2 DRD3 DRD4 HTR1A HTR1B HTR2A
3 axon GO:0030424 9.55 BDNF COMT DRD2 HTR2A SLC6A3
4 dendrite GO:0030425 9.17 BDNF COMT DRD2 HTR1A HTR1B HTR2A
5 integral component of membrane GO:0016021 10.03 COMT DRD2 DRD3 DRD4 HTR1A HTR1B

Biological processes related to Personality Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Name GO ID Score Top Affiliating Genes
1 cellular calcium ion homeostasis GO:0006874 9.92 DRD3 DRD4 HTR2A HTR2C
2 locomotory behavior GO:0007626 9.9 DRD2 DRD3 HTR2C SLC6A3
3 response to toxic substance GO:0009636 9.89 DRD2 MAOB SLC6A4
4 circadian rhythm GO:0007623 9.89 SLC6A4 TPH1 TPH2
5 memory GO:0007613 9.87 BDNF HTR2A SLC6A4
6 positive regulation of fat cell differentiation GO:0045600 9.87 HTR2A HTR2C TPH1
7 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.87 HTR1A HTR1B HTR2A HTR2C
8 social behavior GO:0035176 9.86 DRD3 DRD4 SLC6A4
9 response to ethanol GO:0045471 9.85 DRD2 DRD3 HTR1B MAOB SLC6A3
10 feeding behavior GO:0007631 9.84 DRD2 HTR1B HTR2C
11 release of sequestered calcium ion into cytosol GO:0051209 9.84 DRD2 HTR2A HTR2C
12 behavioral fear response GO:0001662 9.82 DRD4 HTR1A HTR2C
13 response to amphetamine GO:0001975 9.8 DRD2 DRD3 DRD4
14 arachidonic acid secretion GO:0050482 9.8 DRD2 DRD3 DRD4
15 G-protein coupled serotonin receptor signaling pathway GO:0098664 9.79 HTR1A HTR1B HTR2A
16 dopamine receptor signaling pathway GO:0007212 9.78 DRD2 DRD3 DRD4
17 response to cocaine GO:0042220 9.78 DRD2 DRD3 HTR1B SLC6A3
18 vasoconstriction GO:0042310 9.77 HTR1A HTR1B SLC6A4
19 negative regulation of protein secretion GO:0050709 9.76 DRD2 DRD3 DRD4
20 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.75 DRD2 HTR1B HTR2A
21 temperature homeostasis GO:0001659 9.73 DRD2 HTR2A
22 synaptic transmission, dopaminergic GO:0001963 9.73 DRD2 DRD3
23 response to iron ion GO:0010039 9.73 DRD2 SLC6A3
24 prepulse inhibition GO:0060134 9.73 DRD2 DRD3 SLC6A3
25 behavioral response to ethanol GO:0048149 9.72 DRD2 DRD4
26 bone remodeling GO:0046849 9.72 HTR1B TPH1
27 positive regulation of renal sodium excretion GO:0035815 9.72 DRD2 DRD3
28 neurotransmitter biosynthetic process GO:0042136 9.72 SLC6A3 SLC6A4
29 G-protein coupled receptor internalization GO:0002031 9.72 DRD2 DRD3 HTR1B
30 negative regulation of voltage-gated calcium channel activity GO:1901386 9.71 DRD2 DRD4
31 catecholamine metabolic process GO:0006584 9.71 COMT MAOA
32 aromatic amino acid family metabolic process GO:0009072 9.71 TPH1 TPH2
33 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.71 DRD2 DRD3 DRD4
34 behavioral response to cocaine GO:0048148 9.71 DRD2 DRD3 DRD4 HTR2A
35 monoamine transport GO:0015844 9.7 SLC6A3 SLC6A4
36 adenohypophysis development GO:0021984 9.7 DRD2 SLC6A3
37 regulation of hormone secretion GO:0046883 9.7 HTR1A HTR2A
38 regulation of behavior GO:0050795 9.7 HTR1A HTR1B HTR2A
39 dopamine uptake involved in synaptic transmission GO:0051583 9.69 SLC6A3 SLC6A4
40 neurotransmitter catabolic process GO:0042135 9.69 COMT MAOA MAOB
41 indolalkylamine biosynthetic process GO:0046219 9.68 TPH1 TPH2
42 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.68 DRD2 DRD3
43 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.68 HTR1A HTR1B
44 negative regulation of serotonin secretion GO:0014063 9.67 HTR1B MAOB
45 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.67 HTR2A HTR2C
46 regulation of dopamine metabolic process GO:0042053 9.67 DRD4 HTR1A SLC6A3
47 regulation of dopamine secretion GO:0014059 9.67 DRD2 DRD3 HTR1B HTR2A
48 acid secretion GO:0046717 9.66 DRD2 DRD3
49 serotonin biosynthetic process GO:0042427 9.65 TPH1 TPH2
50 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.65 DRD2 DRD4

Molecular functions related to Personality Disorder according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.96 ALDH2 MAOA MAOB TPH1 TPH2
2 obsolete signal transducer activity GO:0004871 9.87 DRD2 DRD3 DRD4 HTR1A HTR1B HTR2A
3 neurotransmitter receptor activity GO:0030594 9.67 HTR1A HTR1B HTR2A HTR2C
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.61 DRD2 DRD3 DRD4
5 dopamine neurotransmitter receptor activity GO:0004952 9.58 DRD2 DRD3 DRD4
6 neurotransmitter:sodium symporter activity GO:0005328 9.57 SLC6A3 SLC6A4
7 G-protein coupled serotonin receptor activity GO:0004993 9.56 HTR1A HTR1B HTR2A HTR2C
8 monoamine transmembrane transporter activity GO:0008504 9.55 SLC6A3 SLC6A4
9 primary amine oxidase activity GO:0008131 9.54 MAOA MAOB
10 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.52 TPH1 TPH2
11 dopamine:sodium symporter activity GO:0005330 9.51 SLC6A3 SLC6A4
12 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.49 HTR2A HTR2C
13 tryptophan 5-monooxygenase activity GO:0004510 9.48 TPH1 TPH2
14 dopamine binding GO:0035240 9.46 DRD2 DRD3 DRD4 SLC6A3
15 serotonin binding GO:0051378 9.26 HTR1A HTR1B HTR2A HTR2C
16 drug binding GO:0008144 9.17 DRD2 DRD3 DRD4 HTR1B HTR2A HTR2C
17 G-protein coupled receptor activity GO:0004930 10 DRD2 DRD3 DRD4 HTR1A HTR1B HTR2A

Sources for Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....